

General Information	
Ministerial Decision Type	Miscellaneous
Report Title	Amendment to the Prescribed List as of 1 August 2024
Minister	Social Security
Signatory	Minister
Lead Department	Strategic Policy, Planning and Performance (SP3)
Lead Directorate	Public Policy (SP3)
Ministerial Decision Summary: Public or Absolutely/Qualified Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Date decision made if different to date 'Ministerial Decision Summary' signed.	Select date.
Report and Supplemental Report Details	
Report Author	Prescribing Advisor
Date of Report	09/07/2024
Supplementary Report Title <i>(If applicable)</i>	Insert Supplementary Report Title.
Supplementary Report Author <i>(If applicable)</i>	Prescribing Advisor
Date of Supplementary Report <i>(If applicable)</i>	
Ministerial Decision Report: Public or Absolutely/Qualified Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Relevant Case/Application/URN <i>(Only complete if making a decision related to an appeal where appropriate or allowed under legislation/case/application)</i>	Insert Relevant Case/Application.
Relevant Proposition Number <i>(Only complete if presenting Comments or if lodging an Amendment)</i>	Insert P. number.
Relevant Scrutiny Report <i>(Only complete if presenting a ministerial response)</i>	Insert S.R. number.
Associated Law(s) and/or Subordinate Legislation	Health Insurance (Jersey) Law 1967
Action required if recommendation agreed	Department to take necessary action.

Resource Implications	There are additional financial and/or manpower implications. Further detail is included in the detail section of the report.
-----------------------	--

Introduction

Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 August 2022

Recommendation

Other

Only insert text if 'Other' selected above.

The Minister accepted recommendations from the PBAC in respect of the following additions and deletions.

1. Additions

- Cyanocobalamin tablets 50mcg, 1mg
- Rimegepant 75mg oral lyophilisates
- Trimbaw NEXThaler 88micrograms/dose / 5micrograms/dose / 9micrograms/dose dry powder inhaler
- Sertraline tablets 25mg (generic)
- Etoricoxib tablets 30mg, 60mg, 90mg, 120mg (generic)
- Dapoxetine tablets 30mg, 60m

2. Deletions

The Committee recommended removal of the following products from the Prescribed List that are either discontinued or rarely used. Alternative products are available on the List where necessary.

- Aspirin 900mg / Metoclopramide 10mg oral powder sachets sugar free
- Lithium citrate 509mg/5ml oral liquid
- Ferrous fumarate 322mg/ folic acid 350microgram tablets (Pregaday)
- Menthol crystals
- Doxepin 25mg & 50mg capsules
- Chlorpromazine 50mg & 100mg tablets, 25mg/5ml & 100mg/5ml oral solution
- Chlorpromazine 25mg/1ml solution for injection ampoules
- Trifluoperazine 1mg tablets and 1mg/5mL oral solution
- Metronidazole 1g suppositories
- Sodium fluoride 1.1mg & 2.2mg chewable tablets
- Sodium fluoride 0.37% oral drops sugar free
- Sodium chloride compound mouthwash
- Sodium fluoride 0.05% mouthwash sugar free
- Saliva Stimulating Tablets (SST)
- Chlorhexidine 0.2% oral spray sugar free
- Balneum (Soya oil 84.75% bath oil)
- Balneum Plus (Soya oil 82.95% / Lauromacrogols 15% bath oil)
- Dermol 600 bath emollient
- Oilatum Plus & Junior bath additive
- Oilatum emollient (liquid paraffin light 634mg/mL 500mL bottle)

3. Items to be reimbursed for generic products only from 1 October 2024

The patents for the following medicines have expired and lower cost generic options are, or soon will be available. Prescribing these products generically will reduce annual expenditure.

- a. Apixaban tablets 2.5mg, 5mg
- b. Rivaroxaban tablets 2.5mg, 10mg, 15mg, 20mg

4. Other recommendations: Medicines for ADHD in adults, children and adolescents (shared care)

The Committee considered further information relating to the application for medicines for ADHD in children and adolescents to be added to the Prescribed List in accordance with shared care protocols, which had been deferred at a previous meeting. In particular, the Committee received responses from primary care medical practices following an email consultation. Representatives of four practices responded highlighting the current shortages in supply of medicines for ADHD (2 responses), concern for a small practice in managing shared care arrangements (1 response) and expressing overall support for the proposal subject to minor changes to the shared care protocol. The Committee also heard about a current workstream around a pathway for patients with ADHD. In view of this feedback, the Committee concluded that it is supportive in principle but is not able to recommend inclusion in the Prescribed List while there are national shortages and before the ADHD pathways have been clarified.

Financial impact

Additions to the prescribed list will incur moderate increase cost in the region of £135,500. Deletions to the list will be cost neutral because equivalent items are available at similar cost. The adoption generic prescribing in relation to Apixaban and Rivaroxaban will reduce cost to the Health Insurance Fund by approximately £1.4 million per annum.

SUPPORTING DOCUMENT: CHANGES TO THE PRESCRIBED LIST

Estimated cost impact of changes to the Prescribed List

Financial impact

The estimated cost impact of the recommended additions to the Prescribed List is shown below with an overall increase in net annual expenditure of around £135,500. However, this is offset by savings of around £1.4million pa through use of generic rather than branded apixaban and rivaroxaban.

Recommendations for removal from the List are not expected to have a material impact on overall expenditure since alternatives are available at broadly similar cost.

Product	Change to Prescribed List	Estimated annual cost impact
Cyanocobalamin tablets 50mcg, 1mg	Addition	£50,000 increase
Rimegepant 75mg oral lyophilisates	Addition	£90,000 increase
Trimbow NEXThaler 88micrograms/dose / 5micrograms/dose / 9micrograms/dose dry powder inhaler	Addition	£18,000 reduction
Sertraline tablets 25mg	Addition	£3,500 increase
Etoricoxib tablets 30mg, 60mg, 90mg, 120mg	Addition	£5,000 increase
Dapoxetine tablets 30mg, 60mg	Addition	£5,000 increase